What is the Oxaliplatin?

Oxaliplatin is White crystalline solid, while it's Molecular Formula is C8H14N2O4Pt. White crystalline solid A antitumor agent with activity against colorectal cancer. Cytotoxicity follows the formation of adducts with DNA

What is the CAS number for Oxaliplatin?

The CAS number of Oxaliplatin is 61825-94-3.

What is Oxaliplatin (61825-94-3) used for?

Eloxatin was launched in France for second-line treatment of metastaticcolorectal cancer. Oxaliplatin is a second generation platinum drug prepared in threesteps from either k2tCl4 or K2Ptl4. It has an antitumor spectrum similar to cisplatin,however, it is more effective against L1210 leukemia and cisplatin resistant L1210. Itis also effective against B16 melanoma but has a dose limiting toxicity of peripheralsensory neuropathy that is reversible upon cessation of the drug. The (R,R)-enantiomer has greater activity than the (S,S)-isomer but this is tumor linedependent, e.g., there was no difference found for P-388 or Sarcoma 180. Clinicaldrug administration based on circadium timing showed it was better tolerated whengiven 16 h after the onset of light. Oxaliplatin binds to guanineN7 and can lead tobidentate chelation that results in the bending of DNA. This feature is recognized byhigh mobility group proteins (HMG) which impedes repair reactions and stopsreplication and transcription.InChI:InChI=1/C6H14N2.C2H2O4.Pt/c7-5-3-1-2-4-6(5)8;3-1(4)2(5)6;/h5-6H,1-4,7-8H2;(H,3,4)(H,5,6);/q;;+2/p-2/t5-,6-;;/m1../s1/rC8H14N2O4Pt/c11-7-8(12)14-15(13-7)9-5-3-1-2-4-6(5)10-15/h5-6H,1-4,9-10H2/t5-,6-/m1/s1

Product Class

61825-94-3

Product Name：Oxaliplatin
Molecular Formula：C₈H₁₄N₂O₄Pt
Purity：99%
Molecular Weight：397.29

Inquiry

Product Details:

CasNo： 61825-94-3

Molecular Formula： C₈H₁₄N₂O₄Pt

Appearance： White crystalline solid

Quality Manufacturer Supply Best Quality Oxaliplatin 61825-94-3 Efficient Transportation

Molecular Formula:C8H14N2O4Pt
Molecular Weight:397.29
Appearance/Colour:White crystalline solid
Boiling Point:193.6oC at 760 mmHg
Flash Point:75oC
PSA：104.64000
LogP:0.61450

Oxaliplatin(Cas 61825-94-3) Usage

Description	Oxaliplatin is a member of the platinum-based chemotherapeutic class of drugs. It is a platinum-containing DNA-crosslinking agent that induces the formation of DNA inter- and intrastrand crosslinks and DNA-protein crosslinks. By inhibiting DNA and RNA synthesis and inducing apoptosis in cancer cells, oxaliplatin exerts its cytotoxic effects.
Chemical Properties	White Crystalline Solid
Originator	Bebiopharm (Switzerland)
Uses	Oxaliplatin is primarily used in the treatment of metastatic colorectal cancer, either as a standalone treatment or in combination with other chemotherapy drugs. It is effective in reducing tumor growth and improving survival outcomes in patients with advanced colorectal cancer. Oxaliplatin is typically administered intravenously, usually as part of a chemotherapy regimen. The dosage and frequency of administration may vary depending on the specific treatment protocol and the patient's individual characteristics.
Brand name	Eloxatin (Sanofi Aventis).
Biological Activity	Antitumor agent that forms platinum-DNA adducts. Causes intra- and interstrand DNA crosslinks blocking DNA replication and transcription. Displays higher cytotoxicity and lower nephrotoxicity than analog cisplatin (cis-Diaminodichloroplatinum ) and shows antitumor activity in cell lines with acquired cisplatin resistance.

InChI:InChI=1/C6H14N2.C2H2O4.Pt/c7-5-3-1-2-4-6(5)8;3-1(4)2(5)6;/h5-6H,1-4,7-8H2;(H,3,4)(H,5,6);/q;;+2/p-2/t5-,6-;;/m1../s1/rC8H14N2O4Pt/c11-7-8(12)14-15(13-7)9-5-3-1-2-4-6(5)10-15/h5-6H,1-4,9-10H2/t5-,6-/m1/s1

61825-94-3 Relevant articles

Oxaliplatin: A review of preclinical and clinical studies

E. Raymond 1, S.G. Chaney 2, A. Taamma 3, E. Cvitkovic 3 4

, Annals of Oncology Volume 9, Issue 10, October 1998, Pages 1053-1071

In phase I trials, the dose-limiting toxicity of oxaliplatin was characterized by transient acute dysesthesias and cumulative distal neurotoxicity, which was reversible within a few months after treatment discontinuation.

Cellular and Molecular Pharmacology of Oxaliplatin

Eric Raymond; Sandrine Faivre; Stephen Chaney; Jan Woynarowski; Esteban Cvitkovic

, Mol Cancer Ther (2002) 1 (3): 227–235.

In in vivo studies, oxaliplatin is active against breast, colon, and gastric cancer; renal cell carcinoma; and sarcoma (16). In addition, oxaliplatin has been tested in vitro and in vivo against cisplatin-resistant cell lines and tumor models, including human ovarian, lung, cervix, colon, and leukemia cell lines.

Phorbiplatin, a Highly Potent Pt(IV) Antitumor Prodrug That Can Be Controllably Activated by Red Light

Wang, Zhigang,Wang, Na,Cheng, Shun-Cheung,Xu, Kai,Deng, Zhiqin,Chen, Shu,Xu, Zoufeng,Xie, Kai,Tse, Man-Kit,Shi, Peng,Hirao, Hajime,Ko, Chi-Chiu,Zhu, Guangyu

, p. 3151 - 3165 (2019)

Selective activation of prodrugs within ...

Cytotoxicity and ROS production of novel Pt(IV)oxaliplatin derivatives with indole propionic acid

Tolan, Dina,Almotairy, Awatif Rashed Z.,Howe, Orla,Devereux, Michael,Montagner, Diego,Erxleben, Andrea

, p. 262 - 267 (2019)

The coordination of biologically active ...

Electrodrugs: An electrochemical prodrug activation strategy

Norman, Daniel J.,González-Fernández, Eva,Clavadetscher, Jessica,Tucker, Lulu,Staderini, Matteo,Mount, Andrew R.,Murray, Alan F.,Bradley, Mark

, p. 9242 - 9245 (2018)

The term electroceutical has been used t...

An intramolecular photoswitch can significantly promote photoactivation of Pt(iv) prodrugs

Chen, Shu,Deng, Zhiqin,Hirao, Hajime,Li, Cai,Wang, Zhigang,Xu, Zoufeng,Yao, Houzong,Zhou, Qiyuan,Zhu, Guangyu

, p. 6536 - 6542 (2021/05/31)

Selective activation of prodrugs at dise...

Stability, Reduction, and Cytotoxicity of Platinum(IV) Anticancer Prodrugs Bearing Carbamate Axial Ligands: Comparison with Their Carboxylate Analogues

Chen, Shu,Gunawan, Yuliana F.,Tse, Man-Kit,Yao, Houzong,Zhou, Qiyuan,Zhu, Guangyu

supporting information, (2020/08/24)

Platinum(IV) complexes containing carbox...

61825-94-3 Upstream products

61848-66-6
(1R,2R)-1,2-diaminocyclohexanedichloroplatinum(II)
33081-83-3
bis(tetrabutylammonium)oxalate
144-62-7
oxalic acid
583-52-8
potassium oxalate

61825-94-3 Downstream products

111263-58-2
cis-oxalic acid (trans-1,2-cyclohexanediamine)dihydroxyplatinum(II)
2864-70-2
5'-AGU-3'

Relevant Products

Tenofovir Disoproxil Fumarate
CAS：202138-50-9
Levofloxacin Hemihydrate
CAS：138199-71-0
Sparsentan
CAS：254740-64-2